Abstract In Canada, the National Advisory Committee on Immunization systematically
reviews the evidence for the effectiveness and safety of new and old vaccines, and sets a …

Résumé La vaccination est l'action de santé publique la plus efficace qui a permis de faire
disparaître ou de réduire très fortement l'incidence des maladies infectieuses. Elle est …

Background Four-component meningococcal B (4CMenB) vaccine is licensed in many
countries but has had limited use in adolescents despite this age group being at increased …

Background The multicomponent meningococcal serogroup B vaccine (4CMenB) has been
licensed in more than 35 countries. However, uncertainties remain about the lowest number …

Vaccination programs employing capsular-based meningococcal vaccines have proved
successful in a variety of settings globally since first introduced over 40 years ago. Similar …

Purpose Meningococcal C conjugate vaccine was included in December 2000 in the
Spanish childhood vaccination at 2, 4 and 6 months of age. In 2006, routine vaccination was …

Comment 1104 www. thelancet. com Vol 383 March 29, 2014 new vaccines, the JCVI can
consider recommending a programme subject to the ability to procure vaccines at a cost …

Introduction: Meningococcal serogroup B disease (MenB) is endemic in the UK and
continues to cause the majority of invasive meningococcal disease. Two broadly protective …

Background Meningococcal serogroup B disease disproportionately affects infants. We
assessed lot-to-lot consistency, safety and immunogenicity, and the effect of concomitant …

Vaccination is the most effective, most reliable and cost-effective approach of protecting
children's and adults' health and preventing infectious diseases. It is the right of each and …